Next Article in Journal
Proteins and Their Interacting Partners: An Introduction to Protein–Ligand Binding Site Prediction Methods
Next Article in Special Issue
FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP
Previous Article in Journal
The Mechanisms of Virulence Regulation by Small Noncoding RNAs in Low GC Gram-Positive Pathogens
Previous Article in Special Issue
Chondrocyte Apoptosis in the Pathogenesis of Osteoarthritis
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(12), 29815-29828;

Transducer of ERBB2.1 (TOB1) as a Tumor Suppressor: A Mechanistic Perspective

Research Institute of Pharmaceutical Science, Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 08826, Korea
Tumor Microenvironment Global Core Research Center, Seoul National University, Seoul 08826, Korea
The Center for Anti-cancer Companion Diagnostics, School of Biological Science, Institutes of Entrepreneurial BioConvergence, Seoul National University, Seoul 08826, Korea
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Anthony Lemarié
Received: 10 September 2015 / Revised: 22 November 2015 / Accepted: 8 December 2015 / Published: 15 December 2015
(This article belongs to the Collection Programmed Cell Death and Apoptosis)
Full-Text   |   PDF [2689 KB, uploaded 15 December 2015]   |  


Transducer of ERBB2.1 (TOB1) is a tumor-suppressor protein, which functions as a negative regulator of the receptor tyrosine-kinase ERBB2. As most of the other tumor suppressor proteins, TOB1 is inactivated in many human cancers. Homozygous deletion of TOB1 in mice is reported to be responsible for cancer development in the lung, liver, and lymph node, whereas the ectopic overexpression of TOB1 shows anti-proliferation, and a decrease in the migration and invasion abilities on cancer cells. Biochemical studies revealed that the anti-proliferative activity of TOB1 involves mRNA deadenylation and is associated with the reduction of both cyclin D1 and cyclin-dependent kinase (CDK) expressions and the induction of CDK inhibitors. Moreover, TOB1 interacts with an oncogenic signaling mediator, β-catenin, and inhibits β-catenin-regulated gene transcription. TOB1 antagonizes the v-akt murine thymoma viral oncogene (AKT) signaling and induces cancer cell apoptosis by activating BCL2-associated X (BAX) protein and inhibiting the BCL-2 and BCL-XL expressions. The tumor-specific overexpression of TOB1 results in the activation of other tumor suppressor proteins, such as mothers against decapentaplegic homolog 4 (SMAD4) and phosphatase and tensin homolog-10 (PTEN), and blocks tumor progression. TOB1-overexpressing cancer cells have limited potential of growing as xenograft tumors in nude mice upon subcutaneous implantation. This review addresses the molecular basis of TOB1 tumor suppressor function with special emphasis on its regulation of intracellular signaling pathways. View Full-Text
Keywords: anti-proliferative; apoptosis; invasion; migration; transducer of erbb2.1; tumor suppressor anti-proliferative; apoptosis; invasion; migration; transducer of erbb2.1; tumor suppressor

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lee, H.S.; Kundu, J.; Kim, R.N.; Shin, Y.K. Transducer of ERBB2.1 (TOB1) as a Tumor Suppressor: A Mechanistic Perspective. Int. J. Mol. Sci. 2015, 16, 29815-29828.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top